NEW YORK (GenomeWeb News) – DNAVision said yesterday that it will offer Ipsogen’s new MapQuant Dx Genomic Grade test through its central lab services in Europe.
 
The MapQuant Dx is a molecular diagnostic, gene expression-based test that measures tumor grade, risk of metastasis, and chemotherapy response, among breast cancer patients. Ipsogen launched the test last week.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.